{
    "clinical_study": {
        "@rank": "78895", 
        "arm_group": [
            {
                "arm_group_label": "Morphine mouthwash", 
                "arm_group_type": "Experimental", 
                "description": "The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University."
            }, 
            {
                "arm_group_label": "Magic mouthwash", 
                "arm_group_type": "Active Comparator", 
                "description": "The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day."
            }
        ], 
        "brief_summary": {
            "textblock": "Oral mucositis is a debilitating side effects of cancer treatment for which there is not\n      much successful treatments at yet. The investigators are going to evaluate the effectiveness\n      of topical morphine compared with a routine mouthwash in managing cancer treatment-induced\n      mucositis. The investigators hypothesize that topical morphine is more effective and more\n      satisfied by patients than the magic mouthwash in reducing severity of cancer\n      treatment-induced oral mucositis."
        }, 
        "brief_title": "Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Stomatitis", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Stomatitis", 
                "Mucositis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Head and neck cancer patients\n\n          -  Severe oral mucositis; grade III or IV of the World Health Organization (WHO) rating\n             of global mucositis\n\n          -  Willingness to participate\n\n        Exclusion Criteria:\n\n          -  History of severe renal or hepatic insufficiency\n\n          -  Collagen-vascular disease\n\n          -  Allergic reaction to morphine\n\n          -  Current smokers or alcohol users\n\n          -  Pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01837446", 
            "org_study_id": "390163"
        }, 
        "intervention": [
            {
                "arm_group_label": "Morphine mouthwash", 
                "intervention_name": "2% morphine solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Magic mouthwash", 
                "intervention_name": "Magnesium aluminum hydroxide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Magic mouthwash", 
                "intervention_name": "2% viscous lidocaine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Magic mouthwash", 
                "intervention_name": "Diphenhydramine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aluminum Hydroxide", 
                "Aluminum hydroxide, magnesium hydroxide, drug combination", 
                "Magnesium Hydroxide", 
                "Diphenhydramine", 
                "Promethazine", 
                "Lidocaine", 
                "Morphine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mucositis", 
            "topical morphine", 
            "pain", 
            "head and neck carcinoma"
        ], 
        "lastchanged_date": "April 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "81849-17395"
                }, 
                "name": "Radiation Oncology Department, Seyed Al-Shohada Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan", 
        "overall_official": {
            "affiliation": "Isfahan University of Medical Sciences", 
            "last_name": "Simin Hemati, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients are visited by a radiation oncologist at baseline, 3rd day, and 6th day of the intervention. The WHO grading system of mucositis is administered for each patient in which, 0 indicates a healed mucositis and no signs or symptoms, 1 indicates mild soreness but not problem in eating, 2 indicates painful erythema, edema, or ulcers but able to eat, 3 indicates severe painful erythema, edema, or ulcers and having problem in eating, and 4 indicates if there is a requirement for parenteral or enteral support.", 
            "measure": "Mucositis severity", 
            "safety_issue": "No", 
            "time_frame": "Up to six days"
        }, 
        "reference": [
            {
                "PMID": "12412178", 
                "citation": "Cerchietti LC, Navigante AH, Bonomi MR, Zaderajko MA, Men\u00e9ndez PR, Pogany CE, Roth BM. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer. 2002 Nov 15;95(10):2230-6. Erratum in: Cancer. 2003 Feb 15;97(4):1137.."
            }, 
            {
                "PMID": "16909245", 
                "citation": "Cerchietti L. Morphine mouthwashes for painful mucositis. Support Care Cancer. 2007 Jan;15(1):115-6; author reply 117. Epub 2006 Aug 15."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837446"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Dr. Simin Hemati", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients also are asked about if pain/discomfort relived by mouthwash and if so for how long (< 1 h, 1 to 2 h, > 2 h). Their satisfaction with treatment is graded as satisfied, tolerable, and intolerable.", 
            "measure": "Patient's satisfaction", 
            "safety_issue": "No", 
            "time_frame": "After six days"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}